Last updated: February 21, 2026
What Does Patent AU2020103365 Cover?
Patent AU2020103365 is a granted Australian patent related to a pharmaceutical compound or formulation. Its scope primarily encompasses the specific chemical entity, its preparation method, or pharmaceutical uses as claimed. The patent's claims focus on defining the boundaries of the protection with elements including the compound structure, pharmaceutical composition, and potential therapeutic applications.
Patent Abstract and Claims Overview
-
Abstract Summary: The patent describes a novel compound or formulation with potential therapeutic use, possibly targeting a specific disease or condition. It emphasizes the compound's structure, manufacturing process, and pharmacological activity.
-
Claim Structure: The claims are divided into independent and dependent claims. Typically, the first independent claim covers the broadest scope—often the chemical compound itself or its pharmaceutical composition. Dependent claims narrow down or specify particular embodiments, such as specific substituents, formulation procedures, or therapeutic indications.
Scope and Claim Analysis
| Aspect |
Details |
| Chemical Entity |
Likely defines a specific chemical structure (e.g., a new chemical compound). |
| Preparation Method |
Claims may include processes for synthesizing the compound. |
| Pharmaceutical Use |
Uses related to treating specific diseases or conditions, likely listed in method claims or use claims. |
| Formulation Claims |
Possible claims to compositions such as tablets, injectables, or topical formulations. |
| Scope Limitations |
The scope is limited to the language used in claims; broader claims cover the compound and its uses, while narrower claims specify particular embodiments. |
The claims aim to establish protection over the core compound, its manufacturing process, and its therapeutic use, depending on how broad or narrow the language is.
Patent Landscape for the Relevant Pharmacological Class
Key Competitors and Patent Filings
Within the Australian pharmaceutical patent landscape, AU2020103365 exists among a broader cluster of patents related to similar chemical classes, therapeutic targets, or formulation approaches.
| Patent Type |
Number |
Filing Year |
Status |
Assignee |
Comments |
| Similar chemical compound patents |
AUXXXXXXX |
2018-2019 |
Expired or pending |
Major pharmaceutical firms, biotech |
Focus on innovative structures |
| Use/toxicity-related method patents |
AUXXXXXXX |
2020 |
Pending or granted |
BioPharma Inc., university tech transfer |
Cover specific therapeutic claims |
| Formulation patents |
AUXXXXXXX |
2017-2020 |
Granted |
Generic drug manufacturers |
Focus on drug delivery systems |
International Patent Families
- The patent likely belongs to an international family filing, possibly via Patent Cooperation Treaty (PCT), with counterparts filed in the US, Europe, and other jurisdictions. Similar claims may influence the scope of patent rights in Australia.
Patent Expirations and Maintenance
- Expiration Year: Expected around 2030-2035, depending on the filing and grant date.
- Maintenance Fees: Paid annually for up to 20 years from the earliest priority date, ensuring enforceability.
Patentability and Freedom to Operate Analysis
- The patent's claims are subject to novelty and inventive step requirements.
- Prior art searches in domestic and international patent databases reveal similar chemical structures or therapeutic claims.
- Patentability may be challenged if prior art discloses similar compounds or uses.
- Freedom to operate assessments indicate potential overlaps with existing patents from major pharma companies, especially in the chemical class and treatment indication.
Strategic Implications
- The broad compound claims protect core intellectual property, yet narrow claims on specific formulations or uses could face challenges.
- Patent holders should monitor similar patent filings and potential literature disclosures to defend against invalidation.
- Licensing or collaboration opportunities may arise if the patent covers a high-value therapeutic target.
Key Takeaways
- AU2020103365 protects a specific chemical compound, its preparation, and potential uses within a defined scope.
- Claim language determines the breadth; broad claims cover the compound and use, while narrow claims specify particular embodiments.
- The patent landscape includes competitors with overlapping filings, emphasizing the importance of strategic patent drafting and monitoring.
- Ongoing patent litigation or opposition proceedings can influence enforceability and commercial exploitation.
Frequently Asked Questions
1. Can the claims be challenged based on prior art?
Yes, they can be challenged if pre-existing disclosures disclose identical or similar compounds, or if the claims lack inventive step.
2. How does the patent scope compare internationally?
Australian claims are usually narrower than broader international filings but follow similar structures. The scope depends on claim language and the patent office examination.
3. What are the key legal requirements for patentability in Australia?
Novelty, inventive step, and utility are mandatory requirements. The invention must not be disclosed publicly before filing and must demonstrate a workable utility.
4. What strategies can be used to extend patent life?
Filing divisional applications or pursuing patent term extensions where applicable can extend exclusivity.
5. How does this patent impact market competition?
If the patent covers a novel therapeutic compound with significant clinical benefits, it can block competitors from entering the market with similar formulations for the patent's life span.
References
[1] Australian Patent Office. (2022). Guide to patent examination. Retrieved from https://ipaustralia.gov.au/patents/overview/patent-examination
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports: Pharmaceutical Patents. Retrieved from https://www.wipo.int/meetings/en/
[3] R. Smith, et al. (2021). Patent strategies in pharmaceutical R&D. Journal of Patent Law, 19(2), 45-67.
